AR122428A1 - Composiciones farmacéuticas y productos farmacéuticos de interleucina-15 humana heterodimérica (hetil-15) - Google Patents

Composiciones farmacéuticas y productos farmacéuticos de interleucina-15 humana heterodimérica (hetil-15)

Info

Publication number
AR122428A1
AR122428A1 ARP210101082A ARP210101082A AR122428A1 AR 122428 A1 AR122428 A1 AR 122428A1 AR P210101082 A ARP210101082 A AR P210101082A AR P210101082 A ARP210101082 A AR P210101082A AR 122428 A1 AR122428 A1 AR 122428A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical
hetyl
human interleukin
compositions
pharmaceutical compositions
Prior art date
Application number
ARP210101082A
Other languages
English (en)
Inventor
Ingo Fischer
Richard Gabriel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR122428A1 publication Critical patent/AR122428A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La divulgación está dirigida a composiciones farmacéuticas estables que comprenden un complejo de IL-15 y IL-15Ra heterodimérica y productos farmacéuticos que comprenden dichas composiciones. La divulgación también está dirigida al uso de estas composiciones (por ejemplo, como parte de un kit que tiene instrucciones de uso) y productos farmacéuticos para el tratamiento de linfopenia, cáncer o enfermedad infecciosa. Reivindicación 1: Una composición farmacéutica que comprende un complejo de IL-15 / IL-15Ra y de aproximadamente 0,0001% a aproximadamente 1% (p/v) de un tensioactivo. Reivindicación 2: La composición de acuerdo con la reivindicación 1, que además comprende de aproximadamente 1 mM a aproximadamente 100 mM de un agente tampón que proporciona un pH en el rango de desde aproximadamente 4,5 a aproximadamente 8,5. Reivindicación 3: La composición de acuerdo con la reivindicación 2, que además comprende de aproximadamente 1 mM a aproximadamente 500 mM de al menos un estabilizador. Reivindicación 4: La composición de acuerdo con cualquiera de las reivindicaciones precedentes, en la cual el tensioactivo es un poloxámero.
ARP210101082A 2020-04-22 2021-04-22 Composiciones farmacéuticas y productos farmacéuticos de interleucina-15 humana heterodimérica (hetil-15) AR122428A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063013801P 2020-04-22 2020-04-22

Publications (1)

Publication Number Publication Date
AR122428A1 true AR122428A1 (es) 2022-09-07

Family

ID=75639945

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101082A AR122428A1 (es) 2020-04-22 2021-04-22 Composiciones farmacéuticas y productos farmacéuticos de interleucina-15 humana heterodimérica (hetil-15)

Country Status (14)

Country Link
US (1) US20210330747A1 (es)
EP (1) EP4138782A1 (es)
JP (1) JP2023523218A (es)
KR (1) KR20230004655A (es)
CN (1) CN115443127A (es)
AR (1) AR122428A1 (es)
AU (1) AU2021260989A1 (es)
BR (1) BR112022020973A2 (es)
CA (1) CA3178895A1 (es)
CO (1) CO2022014867A2 (es)
IL (1) IL297326A (es)
MX (1) MX2022013352A (es)
TW (1) TW202214290A (es)
WO (1) WO2021214658A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202332462A (zh) * 2021-11-18 2023-08-16 大陸商江蘇先聲藥業有限公司 Il-15突變體融合蛋白藥物組合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
MX2007014474A (es) 2005-05-17 2008-02-07 Univ Connecticut Composiciones y metodos para inmunomodulacion en un organismo.
NZ596494A (en) 2006-01-13 2013-07-26 Us Gov Nat Inst Health Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
PT2160401E (pt) 2007-05-11 2014-10-30 Altor Bioscience Corp Moléculas de fusão e variantes de il-15
KR20100120289A (ko) * 2008-01-15 2010-11-15 애보트 게엠베하 운트 콤파니 카게 분말상 단백질 조성물 및 이의 제조 방법
CA2727953C (en) 2008-08-22 2017-05-16 Magna Seating Inc. Disc recliner with reduced backlash
EP3000498B1 (en) * 2009-10-21 2018-04-11 Owen Mumford Limited Autoinjector
JP6251570B2 (ja) 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
ES2811974T3 (es) * 2014-07-29 2021-03-15 Novartis Ag Regímenes de aumento escalonado de la dosis del heterodímero de il-15 e il-15ralfa para tratar afecciones
US20190117690A1 (en) * 2016-04-06 2019-04-25 The University State Of America As Represented By The Secretary Of The Department Of Health And Hum Use of heterodimeric il-15 in adoptive cell transfer
WO2019019998A1 (zh) * 2017-07-25 2019-01-31 江苏恒瑞医药股份有限公司 一种il-15蛋白复合物药物组合物及其用途
WO2019246379A1 (en) * 2018-06-22 2019-12-26 Cugene Inc. Novel interleukin-15 (1l-15) fusion proteins and uses thereof
WO2020219909A1 (en) * 2019-04-26 2020-10-29 Rubius Therapeutics, Inc. Buffered compositions including enucleated erythroid cells

Also Published As

Publication number Publication date
JP2023523218A (ja) 2023-06-02
CN115443127A (zh) 2022-12-06
EP4138782A1 (en) 2023-03-01
KR20230004655A (ko) 2023-01-06
IL297326A (en) 2022-12-01
CA3178895A1 (en) 2021-10-28
AU2021260989A1 (en) 2022-11-17
WO2021214658A1 (en) 2021-10-28
CO2022014867A2 (es) 2022-10-31
BR112022020973A2 (pt) 2022-12-06
MX2022013352A (es) 2022-11-30
US20210330747A1 (en) 2021-10-28
TW202214290A (zh) 2022-04-16

Similar Documents

Publication Publication Date Title
ECSP19030002A (es) 1,2,4-triazolonas 2,4,5-trisustituidas
DOP2018000226A (es) Nuevos derivados de pirazolopirimidina
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
AR127361A2 (es) Composición farmacéutica de partículas de lipoplejos y arn, composición acuosa y método de preparación
UY37789A (es) Nuevos derivados de azaquinolina
UY37606A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
DOP2022000185A (es) Compuestos antivirales y métodos para la administración de los mismos.
PE20191492A1 (es) Composicion farmaceutica que comprende selexipag
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
DOP2022000293A (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
BRPI0416205A (pt) uso de antibióticos como adjuvantes de vacina
UY37832A (es) Dihidrooxadiazinonas
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
CL2020002891A1 (es) Nuevos derivados de quinolina
CL2019002513A1 (es) Composiciones de limpieza cosmética.
UY30535A1 (es) Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones.
MX2020009935A (es) Formulaciones acuosas y estables de anticuerpos anti-tau.
BR112021017890A2 (pt) Composição líquida compreendendo um anticorpo do receptor alfa de interleucina-4 humana
CL2022002919A1 (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune
AR122428A1 (es) Composiciones farmacéuticas y productos farmacéuticos de interleucina-15 humana heterodimérica (hetil-15)
CL2023000524A1 (es) Compuestos fosfolípidos y usos de los mismos
AR077372A1 (es) Composiciones y metodos para tratar infecciones oftalmicas oticas o nasales
CL2023001062A1 (es) Compuestos fosfolípidos y usos de estos
UY37577A (es) Dihidroimidazopiridindionas sustituidas
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico

Legal Events

Date Code Title Description
FB Suspension of granting procedure